Compare · FEMY vs MDLN
FEMY vs MDLN
Side-by-side comparison of Femasys Inc. (FEMY) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FEMY and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.40B, about 136.4x FEMY ($325.5M).
- Over the past year, FEMY is down 66.3% and MDLN is down 17.1% - MDLN leads by 49.3 points.
- MDLN has been more active in the news (20 items in the past 4 weeks vs 2 for FEMY).
- MDLN has more recent analyst coverage (25 ratings vs 3 for FEMY).
- Company
- Femasys Inc.
- Medline Inc.
- Price
- $5.37+1661.23%
- $33.80+0.58%
- Market cap
- $325.5M
- $44.40B
- 1M return
- -40.01%
- -19.55%
- 1Y return
- -66.33%
- -17.07%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2025
- News (4w)
- 2
- 20
- Recent ratings
- 3
- 25
Femasys Inc.
Femasys Inc., a biomedical company, researches, develops, and manufactures medical devices for the women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a sterile, single-use disposable endocervical curettage product; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Latest FEMY
- Femasys Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Femasys Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Femasys Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
- SEC Form 10-Q filed by Femasys Inc.
- Femasys Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
- Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
- SEC Form DEF 14A filed by Femasys Inc.
- SEC Form DEFA14A filed by Femasys Inc.
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)